Skip to main content
. 2019 Dec 28;22(7):1006–1017. doi: 10.1093/neuonc/noz244

Fig. 2.

Fig. 2

(A) Five-year survival (OS) of 143 consecutive patients treated according to the EU-RHAB consensus therapy. The 5-year overall survival (5y-OS) of the EU-RHAB cohort of 143 patients with ATRT was 34.7 ± 4.5% while the 5-year event-free survival (5y-EFS) of the same cohort was 30.5 ± 4.2%. OS was defined as the time from diagnosis until death of any cause or last visit. EFS was defined as the time from diagnosis until first progression, relapse, death of any cause, or last contact. (B) Age <1 year at diagnosis as an independent negative prognostic factor. The 5-year OS was 45.3 ± 6% for patients diagnosed after age 1 and 16.7 ± 5.7% for those <1 year at diagnosis. (C) Patients of the ATRT-TYR group demonstrate superior outcome compared with those of the ATRT-SHH and ATRT-MYC groups. The 5-year OS was superior in patients of the ATRT-TYR subgroup (48.8 ± 10.2%) versus 19 ± 8.8% for ATRT-SHH and final level not reached for the ATRT-MYC DNA-methylation subgroup (36.4 ± 12.5%). (D) Patients of the ATRT-TYR DNA-methylation subgroup have a significantly better prognosis compared with those of the non-TYR group. The 5-year OS was superior in patients of the ATRT-TYR subgroup (48.8 ± 10.2%) compared with those of the non-TYR subgroup (23.5 ± 7.7%).